JP2018516932A5 - - Google Patents

Download PDF

Info

Publication number
JP2018516932A5
JP2018516932A5 JP2017562678A JP2017562678A JP2018516932A5 JP 2018516932 A5 JP2018516932 A5 JP 2018516932A5 JP 2017562678 A JP2017562678 A JP 2017562678A JP 2017562678 A JP2017562678 A JP 2017562678A JP 2018516932 A5 JP2018516932 A5 JP 2018516932A5
Authority
JP
Japan
Prior art keywords
amino
sulfonyl
phenyl
pyridine
carboxamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017562678A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018516932A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2016/000821 external-priority patent/WO2016193812A1/en
Publication of JP2018516932A publication Critical patent/JP2018516932A/ja
Publication of JP2018516932A5 publication Critical patent/JP2018516932A5/ja
Pending legal-status Critical Current

Links

JP2017562678A 2015-06-02 2016-05-25 置換ピリジンおよび使用方法 Pending JP2018516932A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562169881P 2015-06-02 2015-06-02
US62/169,881 2015-06-02
PCT/IB2016/000821 WO2016193812A1 (en) 2015-06-02 2016-05-25 Substituted pyridines and method of use

Publications (2)

Publication Number Publication Date
JP2018516932A JP2018516932A (ja) 2018-06-28
JP2018516932A5 true JP2018516932A5 (enExample) 2019-06-27

Family

ID=57440295

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017562678A Pending JP2018516932A (ja) 2015-06-02 2016-05-25 置換ピリジンおよび使用方法

Country Status (23)

Country Link
US (1) US10047051B2 (enExample)
EP (1) EP3303294A1 (enExample)
JP (1) JP2018516932A (enExample)
KR (1) KR20180029204A (enExample)
CN (1) CN107922338A (enExample)
AR (1) AR106865A1 (enExample)
AU (1) AU2016272702A1 (enExample)
BR (1) BR112017026132A2 (enExample)
CA (1) CA2988046A1 (enExample)
CL (1) CL2017003067A1 (enExample)
CO (1) CO2017012566A2 (enExample)
CR (1) CR20170595A (enExample)
DO (1) DOP2017000278A (enExample)
EC (1) ECSP17085494A (enExample)
HK (1) HK1253581A1 (enExample)
IL (1) IL256032A (enExample)
MX (1) MX2017015591A (enExample)
PE (1) PE20180457A1 (enExample)
PH (1) PH12017502201A1 (enExample)
RU (1) RU2017146661A (enExample)
TW (1) TW201713621A (enExample)
UY (1) UY36702A (enExample)
WO (1) WO2016193812A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210401869A1 (en) * 2015-02-20 2021-12-30 Rosalind Franklin University Of Medicine And Science Antisense Compounds Targeting Genes Associated with Cystic Fibrosis
US10138227B2 (en) * 2016-06-03 2018-11-27 Abbvie S.Á.R.L. Heteroaryl substituted pyridines and methods of use
TW201811766A (zh) 2016-08-29 2018-04-01 瑞士商諾華公司 N-(吡啶-2-基)吡啶-磺醯胺衍生物及其用於疾病治療之用途
US9981910B2 (en) 2016-10-07 2018-05-29 Abbvie S.Á.R.L. Substituted pyrrolidines and methods of use
US10399940B2 (en) 2016-10-07 2019-09-03 Abbvie S.Á.R.L. Substituted pyrrolidines and methods of use
WO2018116185A1 (en) 2016-12-20 2018-06-28 AbbVie S.à.r.l. Deuterated cftr modulators and methods of use
TW201831471A (zh) 2017-02-24 2018-09-01 盧森堡商艾伯維公司 囊腫纖化症跨膜傳導調節蛋白的調節劑及其使用方法
US10988454B2 (en) 2017-09-14 2021-04-27 Abbvie Overseas S.À.R.L. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
WO2019193062A1 (en) 2018-04-03 2019-10-10 Abbvie S.Á.R.L Substituted pyrrolidines and their use
CN113423702A (zh) * 2019-02-06 2021-09-21 诺华股份有限公司 N-(吡啶-2-基)吡啶-磺酰胺衍生物及其在治疗疾病中的用途
EP3747882A1 (en) 2019-06-03 2020-12-09 AbbVie Overseas S.à r.l. Prodrug modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
WO2021011327A1 (en) 2019-07-12 2021-01-21 Orphomed, Inc. Compound for treating cystic fibrosis
EP4274828A1 (en) 2021-01-06 2023-11-15 AbbVie Global Enterprises Ltd. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
US20220213041A1 (en) 2021-01-06 2022-07-07 AbbVie Global Enterprises Ltd. Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use
KR20240041946A (ko) 2021-08-19 2024-04-01 신젠타 크롭 프로텍션 아게 디아미드 저항성 해충을 방제하는 방법 및 그를 위한 화합물
EP4396176A1 (en) * 2021-09-03 2024-07-10 Genzyme Corporation Indole compounds and uses thereof in the treatement of cystic fibrosis

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005251745A1 (en) 2004-06-04 2005-12-22 The Regents Of The University Of California Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof
PL2489659T3 (pl) 2004-06-24 2018-06-29 Vertex Pharma Modulatory transporterów posiadających kasetę wiążącą atp
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
NZ581419A (en) 2007-05-25 2012-05-25 Vertex Pharma Modulators of cystic fibrosis transmembrane conductance regulator
ES2654395T3 (es) 2007-12-10 2018-02-13 Novartis Ag Análogos de amilorida espirocíclicos como bloqueantes de ENaC
NZ586271A (en) 2007-12-13 2012-08-31 Vertex Pharma Fused pyrimidinone derivatives as modulators of cystic fibrosis transmembrane conductance regulator
US8436014B2 (en) 2008-10-23 2013-05-07 Vertex Pharmaceutical Incorporated Solid forms of N-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluorormethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihyroquinoline-3-carboxamide
WO2010078103A1 (en) 2008-12-30 2010-07-08 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US8247436B2 (en) * 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
ES2882807T3 (es) 2011-09-16 2021-12-02 Novartis Ag Heterociclil carboxamidas N-sustituidas
US9034879B2 (en) 2011-09-16 2015-05-19 Novartis Ag Heterocyclic compounds for the treatment of CF
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
WO2013043720A1 (en) 2011-09-20 2013-03-28 The University Of North Carolina At Chapel Hill Regulation of sodium channels by plunc proteins
US9382254B2 (en) * 2013-05-07 2016-07-05 Galapagos Nv Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis
DK3030568T3 (en) 2013-08-08 2019-01-07 Galapagos Nv THIENO [2,3-C] PYRANES AS CFTR MODULATORS
WO2015138934A1 (en) 2014-03-13 2015-09-17 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
CA2942386A1 (en) 2014-03-13 2015-09-17 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
WO2017196843A1 (en) * 2016-05-09 2017-11-16 Proteostasis Therapeutics, Inc. Methods of identifying cftr modulators

Similar Documents

Publication Publication Date Title
JP2018516932A5 (enExample)
RU2017146661A (ru) Замещенные пиридины и способ их применения
RU2015143917A (ru) Индуцирующие апоптоз средства для лечения злокачественной опухоли и иммунологических и аутоиммунных заболеваний
JP2014521696A5 (enExample)
JP2017530999A5 (enExample)
RU2011127402A (ru) Селективные к bcl-2 агенты, вызывающие апоптоз, для лечения рака и иммунных заболеваний
CN1902196B (zh) 噻唑衍生物
RU2017116598A (ru) Соединения и композиции для модуляции киназной активности мутантов egfr
JP5518838B2 (ja) ピロリジノングルコキナーゼアクチベーター
RU2347777C2 (ru) Двойные агонисты nk1/nk3 для лечения шизофрении
JP2015529192A5 (enExample)
AU2014291711B2 (en) Autotaxin inhibitors comprising a heteroaromatic ring-benzyl-amide-cycle core
JP2018524343A5 (enExample)
JP2005523901A5 (enExample)
RU2011127232A (ru) Апоптоз-индуцирующие средства для лечения рака и иммунных и аутоиммунных заболеваний
RU2012127760A (ru) Bcl-2-селективные апоптоз-индуцирующие средства для лечения рака и иммунных заболеваний
HRP20230294T1 (hr) Modulatori tmem16a
JP2019531274A5 (enExample)
RU2001126337A (ru) Соединения, пригодные в качестве противовоспалительных агентов
JP2012532888A5 (enExample)
JP6074043B2 (ja) 新規なモルホリン誘導体またはその塩
ME02205B (me) INDUKUJUĆI AGENSI APOPTOZE ZA LEČENJE KANCERA I IMUNIH l AUTOIMUNIH OBOLJENJA
HRP20240297T1 (hr) Derivati alfa-d-galaktopiranozida
CN109923113A (zh) 作为GABA A α5 PAM的新型异噁唑基醚衍生物
JP2018505145A5 (enExample)